Main findings
We found that the higher cardiovascular burden, as measured by FGCRS, was associated with an increased risk of dementia. This association was further supported by the association with greater WMHs, smaller total grey matter and smaller cortical volumes. These associations were largely free of genetic modification in dementia. Furthermore, incident CVD played a partial role in the association of cardiovascular risk burden with dementia, and higher cardiovascular risk burden was also associated with elevated dementia risk in the absence of CVD.
Our study extended the current understanding of overall cardiovascular risk burden and dementia risk by examining the potential role of CVD events. Previous studies with limited sample sizes reported elevated dementia risk with a higher cardiovascular risk burden.3 6 10 20 However, most studies did not account for CVD events, and in only a few studies, CVD events were adjusted as covariates. For instance, CVD events were not addressed in either the Framingham Heart Study, including 12115 or 3547 participants based on German insurance data.8 Baseline CVD was adjusted in the Finnish Cardiovascular Risk Factors, Aging, and Dementia Study, which included 1449 participants.10 Nevertheless, reverse causation may exist since drastic changes in lifestyle may occur after CVD diagnosis. In addition, CVD treatment could influence both the cardiovascular risk burden and the risk of dementia.13 Our research was conducted among participants without baseline CVD, which may result in a relatively stable FGCRS and minimise the potential impact of treatment. Our findings of elevated dementia risk and higher cardiovascular risk burden align with a previous study in French participants aged 65 years or older without a history of CVD.4
Our study suggested a partial role of incident major CVD in the occurrence of dementia. The association of cardiovascular risk burden in our study with dementia risk was attenuated after adjusting for incident CHD and stroke, similar to the slightly attenuated association for vascular dementia after adjusting for interim stroke in the Chicago Heart Association Detection Project in Industry Study.6 Meanwhile, we found that only 14% of dementia occurrences in our study could be attributed to incident major CVD events, suggesting CVD events do not fully account for the association between cardiovascular risk burden and dementia. This result is supported by the strong association of cardiovascular risk burden with all-cause dementia among participants without incident stroke and CHD events during follow-up in our study, consistent with the results among participants free of CVD over the follow-up among the British civil service population in the Whitehall II Study.3 The limited mediating role of CVD indicates that changeable individual components of the cardiovascular risk burden could be targeted to reduce dementia risk in addition to CVD onset. The pathogenesis of dementia subtypes varies: Alzheimer’s disease is characterised by extracellular amyloid plaques and intracellular neurofibrillary tangles,21 whereas vascular dementia is caused by reduced blood flow to the brain. Nevertheless, existing studies were unable to examine the associations for dementia subtypes due to the limited sample sizes. The Rush Memory and Aging Project especially examined FGCRS with Alzheimer’s disease,20 but dementia cases from other causes were limited (n=35). The UKB offers a relatively large sample for major subtypes of dementia, which has facilitated findings such as the disparate associations of telomere length with Alzheimer’s disease and vascular dementia.22 We provided additional evidence on the association of a higher cardiovascular risk burden with an elevated risk of Alzheimer’s disease, vascular dementia and other dementias.
WMHs are the consequence of cerebral small vessel disease, and the presence of large confluent WMHs has been associated with decreased cognitive function, suggesting a causal link with dementia.23 Alzheimer’s disease signature based on cortical thinning could identify subtle but reliable atrophy in asymptomatic individuals nearly a decade before dementia.24 Compared with the Rush Memory and Aging Project,17 our study validated in a larger sample that cardiovascular risk burden was associated with greater WMH volume, smaller total grey matter and smaller cortical volumes, independent of a comprehensive genetic risk score of dementia rather than APOE ε4 status alone. The PRS incorporates a much more comprehensive indicator of genetic risk and provides a quantitative measurement that allows for more genetic variations in dementia. Cardiovascular risk burden was not found to be associated with whole brain volume in our study, possibly due to a relatively younger population with moderate follow-up duration. The Framingham Heart Study Offspring Cohort7 and the CARDIA Study16 suggested a time window (14 and 25 years, respectively) between cardiovascular risk burden measurement and whole brain atrophy.
Few studies have evaluated the modification role of the overall genetic predisposition to dementia on the association between cardiovascular burden and dementia-related outcomes. Most of the studies only used APOE genotype as a covariate3 4 10 11 or a stratification variable.4 In the Rotterdam Study among 6352 individuals aged 55 years with a median follow-up of 14.1 years, an interaction was found between the Ideal Cardiovascular Health Score and APOE genotype on dementia risk, with no significant association among APOE ε4 carriers.25 In the Atherosclerosis Risk in Communities Study with 2226 incident dementia cases identified over a median follow-up of 25 years, no interaction was found between APOE status and cardiovascular health on dementia risk.11 The inconsistent findings of interactions between cardiovascular burden and genetic risk of dementia may partly be due to the incomplete representativeness of the APOE genotype for the genetic burden of dementia. Our study did not observe a significant interaction between cardiovascular burden and the genetic background of dementia risk from a more comprehensive set of genetic variants. This aligns with the result from the Framingham Heart Study offspring cohort,5 suggesting that reducing cardiovascular burden may be equally efficient for preventing dementia regardless of the genetic risk level.
The elevated dementia risk related to higher cardiovascular risk burden is partially due to chronic cerebral hypoperfusion. Cerebrovascular reserve serves as a potential biomarker for monitoring pressure–perfusion–cognition relationships since the decline of vascular reserve capacity can lead to impairment in neurovascular coupling and reduced cognitive function.26 Mechanisms associated with stroke may also include enhanced amyloid deposition, the additive effect of amyloid deposition on cerebrovascular damage, inflammation and disturbed cholesterol metabolism.27 The most common and plausible mechanisms that link atrial fibrillation, ischaemic heart disease and heart failure to dementia may involve cerebral hypoperfusion and hypoxia, cerebral ischaemia or microbleeds, and the release of natriuretic peptides.28 The unexplained dementia risk of the cardiovascular burden caused by major CVD events may involve other mechanisms, including cerebral small vessel lesions and microinfarctions not reaching the stage of clinically diagnosed CVD, oxidative stress, inflammation and aberrant brain energy metabolism,29 which warrant confirmation by further studies.
Limitations
The UKB, covering half a million people with diverse data, enables detailed analysis of gene-environment interactions, effect modification by possible confounding factors, dose-response relations and brain structure, which is a major strength of our study. However, several limitations warrant attention. First, dementia diagnosis was based on hospital admission and death registry data, and underdiagnosis is inevitable. Nevertheless, validation research has established good sensitivity for hospital admission and death registry data compared with expert adjudication of full-text medical records.30 Second, participants included in the current study were Caucasians, and caution should be paid when extrapolating findings to the broader population. However, there is no reason to expect that the association would be qualitatively different across races and ethnicities. Third, FGCRS was only assessed at baseline; therefore, potential associations of changes in cardiovascular burden with dementia and brain structure could not be evaluated. Fourth, although we have carefully adjusted for a large set of established major environmental and genetic risk factors, residual confounding is inevitable in an observational study. Finally, reverse causation may be a concern since cardiovascular burden may be modified by the intervention of caregivers within a short period before the diagnosis of dementia. Nevertheless, associations remained similar when dementia cases within 2 years of follow-up were excluded.